May 14, 2021 10:34am

A scorecard of earnings releases of 35 covered companies

The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"

28 to date

 


COMPANY 

SYMBOL NET INCOME Q1/21 LOSS Q1/21 LPS Q1/21 CASH RUNWAY

Chinook Therapeutics

formerly, Aduro

Biotech (ADRO)

KDNY   -$37.2 m -$0.08 $222.6 m 2023

Alnylam

Pharmaceuticals

ALNY   -$200 M -$1.71

$1.71 B

2024
Applied Genetic Technologies AGTC Monday, 5/17

 

     

Athersys

 

ATHX   -$26.5 m -$0.13 $64.2 m 2022

Adverum

Biotechnologies

ADVM   -$28.4 m -$0.29 $404 m Q1/23

AxoGen

 

AXGN   -$6.7 m -$0.16 $97.2 m Q1/23

Bellicum

Pharmaceuticals

BLCM

 

       

BioLife

Solutions

BLFS

 

-$1.1 m -$0.03

 $89.1 m

2023
Biostage BSTG         Q1/21

bluebird bio

 

BLUE   -$205.8 m -$3.07 $1.09 B 2023

Brainstorm Cell Therapeutics

 

BCLI   -$6.6 m -$0.19 $40 M 2022

Caladrius

Biosciences.

CLBS   -$8.1 m -$0.19 $111.5 m

2023

Cellectis SA CLLS

 

-$12 m -$0.28 $231 m 2023

CRISPR

Therapeutics

CRSP   -$113.2 M -$1.51 $1,806 m 2023

Editas

Medicine

EDIT

 

-$56.7 m -$0.86 $732.2 m 2023

Fate

Therapeutics

FATE   -$45 m -$0.48 $888.4 m 2023

Global Blood

Therapeutics

GBT   -$74.9 m -$1.21 $482 m 1H/2023

Homology

Medicine

FIXX   -$1.1 m -$0.02

$188.6 m

$49.4 m raised in April

Q1/23

Intellia

Therapeutics

NTLA   -$46.2 m -$0.69 $600.8 m 2023

Precigen

formerly

Intrexon 

PGEN   -$17.3 m -$0.11 $209.3 m 2022

Ionis

Pharmaceuticals

IONS

 

 

-$90 m -$0.64 $1.8 B N/A
Mesoblast MESO  

 

 

 

 
MiMedx Group

MDXG

 

-$8.41 m

-$0,09 $84.7 m 2023

Pluristem

Therapeutics

PSTI         2022

ReNeuron

Group

RENE.L          

Regenxbio

 

RGNX   -$50.1 m -$1.20 $656.5 m 2H/23

Sage

Therapeutics

SAGE   -$95.8 m -$1.64 $2 B N/A

Sangamo

Biosciences

SGMO   -$45.9 m -$0.32 $629.5 m 2024

Solid

Biosciences

SLDB  

-$16.9 m

-$0.19 $268.5 m Q4/22

Ultragenyx

Pharmaceuticals

RARE   -$136.1 m -$2.03 $1 B N/A 

uniQure N.V.

 

QURE   -$41.6 m -$0.91

$260.8 m

$450 from CSL Behring

used $35 of $135 from Hercules -debt vehicle

$200 m fro SVBLeerink

2H/24

Verastem

Oncology

VSTM   -$15 m -$0.09 $127.1 m Q1/24

Vericel

 

VCEL   -$3.3 m -$0.07 $110 m 2023

Voyager

Therapeutics

VYGR

 

-$21.6 m -$0.58 $153.1 m Q1/23